Why PCSK9 Inhibition Became the Most Competitive Target in Cardiovascular Medicine

PCSK9 inhibition lowers LDL cholesterol by blocking the protein that degrades LDL receptors on liver cells — and every percentage-point reduction in LDL-C translates directly into reduced cardiovascular risk. When PCSK9 binds to the LDL receptor (LDLR) on hepatocyte surfaces, it triggers receptor degradation; without that interaction, LDLR cycles back to the cell surface and continues clearing LDL from the bloodstream. Blocking this single protein–protein interaction has proven to be one of the most effective pharmacological strategies in modern cardiovascular medicine, as recognised by regulatory agencies including the FDA and scientific bodies such as the European Society of Cardiology.

Approved injectable PCSK9 inhibitors — the monoclonal antibodies evolocumab and alirocumab — deliver substantial LDL-C reductions but require subcutaneous injection every two to four weeks. That delivery barrier has limited uptake, particularly among patients who are needle-averse, live in areas with limited healthcare access, or manage multiple chronic conditions. The commercial opportunity for an oral PCSK9 inhibitor is therefore significant: a daily pill that matches even a fraction of the efficacy of injectable antibodies could address a far larger patient population. According to data tracked by the World Health Organization, cardiovascular disease remains the leading cause of death globally, underscoring the scale of unmet need that oral PCSK9 inhibitors are designed to address.

MK-0616: How a Macrocyclic Polypeptide Solves the Oral Bioavailability Problem

MK-0616 is an oral PCSK9-inhibiting macrocyclic polypeptide developed by Merck Sharp & Dohme LLC that directly blocks the interaction between PCSK9 and the LDL receptor. The macrocyclic peptide scaffold — a ring-shaped peptide structure — is the key engineering choice that distinguishes MK-0616 from both conventional small molecules and injectable antibodies. Standard peptides are rapidly degraded in the gastrointestinal tract and have poor oral bioavailability; macrocyclisation constrains the molecule’s conformation, increases metabolic stability, and can improve membrane permeability sufficiently to allow oral dosing.

Patent filings from Merck Sharp & Dohme LLC describe the core invention as polypeptides that inhibit the interaction between PCSK9 and LDLR, with pharmaceutical compositions designed for oral administration to treat diseases associated with elevated LDL cholesterol levels. The structural patents — filed across multiple US and PCT applications beginning in April 2022 — cover a range of polypeptide sequences and structural variants, reflecting the breadth of Merck’s medicinal chemistry effort to optimise the macrocyclic scaffold for potency, selectivity, and oral pharmacokinetics.

“MK-0616 represents the first oral PCSK9 inhibitor to advance to Phase III cardiovascular outcomes testing — a milestone that required solving the protein–protein interaction targeting problem and the oral bioavailability problem simultaneously.”

The challenge of inhibiting a protein–protein interaction (PPI) with a small or medium-sized molecule is well-established in drug discovery: PPI interfaces are typically large, flat, and lack the deep binding pockets that conventional small molecules exploit. Macrocyclic peptides occupy a chemical space between small molecules and biologics — large enough to engage extended PPI surfaces, but potentially small enough for oral delivery. Merck’s structural patent filings, which span more than 20 patent families, suggest the company explored extensive structure–activity relationships before selecting MK-0616 as the clinical candidate. Research published in peer-reviewed journals tracked by Nature has highlighted macrocyclic peptides as an emerging modality for previously undruggable targets.

Merck’s Patent Portfolio: A Combination Therapy Fortress Around MK-0616

Merck Sharp & Dohme LLC’s patent strategy for MK-0616 has two distinct layers: a structural foundation covering the macrocyclic polypeptide molecules themselves, and a combination therapy layer covering MK-0616 co-administered with every major lipid-lowering agent class. The structural patents — filed under PCT and US jurisdictions from April 2022 onward — cover polypeptide sequences, structural properties, methods of preparation, and pharmaceutical compositions for treating diseases associated with elevated LDL cholesterol levels.

The February 2024 combination therapy patent cluster is strategically significant. Merck filed seven separate PCT applications (WO2024030529A1 through WO2024030537A1) covering MK-0616 in combination with:

• Statins (the standard first-line lipid-lowering therapy)
• Ezetimibe (cholesterol absorption inhibitor)
• Bempedoic acid (ATP-citrate lyase inhibitor)
• Inclisiran (siRNA-based PCSK9 inhibitor)
• Statin plus ezetimibe
• Statin plus bempedoic acid
• Statin plus ezetimibe plus bempedoic acid

The inclusion of inclisiran in the combination patent portfolio is particularly notable: inclisiran is itself a PCSK9 inhibitor (an siRNA that silences PCSK9 gene expression), meaning Merck has filed IP covering the combination of two distinct PCSK9 inhibition mechanisms. This dual-PCSK9-inhibition strategy — one agent blocking the protein, another blocking its synthesis — reflects an emerging clinical hypothesis about additive or synergistic LDL-C lowering. Patent analysis tools on the PatSnap Life Sciences platform can help researchers map the full competitive landscape around these overlapping combination claims.

VICTORION-ORAL and What Phase III Must Prove

VICTORION-ORAL is Merck’s Phase III cardiovascular outcomes trial for MK-0616, evaluating whether the oral PCSK9 inhibitor reduces major adverse cardiovascular events (MACE) in patients with hypercholesterolemia or established cardiovascular disease. Reaching Phase III with an oral PCSK9 inhibitor is a significant milestone: prior to MK-0616, no oral agent had successfully navigated the pharmacokinetic and pharmacodynamic hurdles required to demonstrate sufficient PCSK9 inhibition for cardiovascular outcomes testing.

The VICTORION-ORAL trial design follows the established template of cardiovascular outcomes trials for lipid-lowering therapies. Regulatory precedent set by the FOURIER trial for evolocumab and the ODYSSEY OUTCOMES trial for alirocumab — both of which demonstrated significant reductions in MACE on top of statin therapy — establishes the benchmark that MK-0616 must meet or approach. The ClinicalTrials.gov registry documents the trial’s enrollment parameters and primary endpoints for public reference.

Merck’s combination therapy patent filings provide a window into the likely trial population: patents covering MK-0616 plus statin, MK-0616 plus statin plus ezetimibe, and MK-0616 plus statin plus bempedoic acid suggest the trial is designed to enrol patients already on maximally tolerated background lipid-lowering therapy — the population most likely to have residual LDL-C elevation and the highest cardiovascular risk. This mirrors the design of the pivotal FOURIER and ODYSSEY OUTCOMES trials and positions MK-0616 for a label in the highest-need patient segment.

The Small-Molecule PCSK9 Pipeline Race: Who Else Is Competing

MK-0616 is the most advanced oral PCSK9 inhibitor in clinical development, but it is not the only candidate in the race. The PCSK9 small-molecule and peptide pipeline reflects broad industry interest in converting a validated injectable target into an oral therapy. The patent landscape — searchable through platforms such as PatSnap — shows multiple assignees pursuing distinct chemical approaches to oral PCSK9 inhibition, from traditional small molecules targeting allosteric sites to other macrocyclic peptide scaffolds.

The competitive dynamics are shaped by several factors. First, the IP window: Merck’s structural patents filed from April 2022 onward provide protection for the specific macrocyclic polypeptide sequences in MK-0616, but competitors pursuing different molecular scaffolds are not blocked by those claims. Second, the clinical timeline: VICTORION-ORAL’s Phase III status gives Merck a significant lead, but cardiovascular outcomes trials typically run for three to five years, leaving a window for fast-following competitors to generate Phase II data. Third, the combination therapy patent layer: Merck’s broad combination filings create freedom-to-operate considerations for any competitor seeking to position their oral PCSK9 inhibitor as an add-on to statins or ezetimibe — the most commercially relevant combination.

The patent data also reveals that Merck’s combination strategy extends to inclisiran co-administration (WO2024030536A1), which is scientifically provocative: combining an oral PCSK9 protein inhibitor with an siRNA that silences PCSK9 gene expression would theoretically achieve near-complete PCSK9 pathway suppression. Whether this combination advances clinically will depend on safety, tolerability, and cost-effectiveness data. Standards bodies such as NICE in the UK and equivalent health technology assessment agencies globally will evaluate whether the incremental LDL-C reduction justifies combination use.

“Merck’s filing of a combination patent covering MK-0616 plus inclisiran — two agents targeting the same pathway by different mechanisms — signals that the company is thinking beyond monotherapy and toward maximal PCSK9 pathway suppression.”

For drug discovery teams and IP strategists monitoring this space, the key intelligence question is not simply whether MK-0616 will succeed in VICTORION-ORAL, but how the competitive patent landscape will evolve as Phase III data emerge. Positive outcomes data typically triggers a second wave of combination and formulation patents from the innovator, alongside accelerated filing activity from competitors seeking to design around the lead compound. Patent analytics tools available through the PatSnap Life Sciences platform allow teams to monitor this evolution in near real time.